Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.58 |
| ▸ | CD274 | Q9NZQ7 | 11/20 | 0.44 |
| ▸ | SLC26A4 | O43511 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL562221 | 0.99 | FFAR1 (0.57) | FFAR1CD274SLC26A4FFAR4PDCD1 | |
| SCHEMBL562220 | 0.90 | FFAR1 (0.51) | FFAR1CD274SLC26A4PDCD1HDAC6 | |
| SCHEMBL13084417 | 0.90 | FFAR1 (0.51) | FFAR1CD274PDCD1HDAC6 | |
| SCHEMBL562634 | 0.90 | FFAR1 (0.47) | FFAR1CD274 | |
| SCHEMBL562240 | 0.90 | FFAR1 (0.47) | FFAR1CD274 | |
| SCHEMBL561854 | 0.90 | FFAR1 (0.47) | FFAR1CD274 | |
| SCHEMBL10203819 | 0.89 | FFAR1 (0.50) | FFAR1CD274PDCD1HDAC6 | |
| SCHEMBL563234 | 0.86 | CD274 (0.45) | FFAR1CD274 | |
| SCHEMBL563235 | 0.86 | CD274 (0.45) | FFAR1CD274 | |
| SCHEMBL10203948 | 0.83 | CD274 (0.42) | FFAR1CD274PDCD1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2423176-A1 | CARBOXYLIC ACID COMPOUND | Astellas Pharma Inc. (JP) | 2012-02-29 | — | — | EP | claimed |
| US-20120035196-A1 | CARBOXYLIC ACID COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | claimed |
| EP-2423176-A1 | CARBOXYLIC ACID COMPOUND | Astellas Pharma Inc. (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-20120035196-A1 | CARBOXYLIC ACID COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20120035196-A1 | CARBOXYLIC ACID COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20120035196-A1 | CARBOXYLIC ACID COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035196-A1 | CARBOXYLIC ACID COMPOUND | GPR119, GPR65, GPR55 | FFAR1 23/4885CD274 3683/4885SLC26A4 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.